Furthermore, the inhibition of HDAC and simultaneous activation of RXR significantly enhanced the efficacy of cisplatin by increasing HtrA1 expression in CDDP-resistant NSCLC xenograft tumors in vivo. The gene discussed is HTRA1; the disease is non-small cell lung carcinoma.